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Objectives. To evaluate the frequency of seizures in primary antiphospholipid syndrome (PAPS) and their possible clinical
and laboratory associations. Methods. Eighty-eight PAPS patients (Sydney’s criteria) were analyzed by a standard interview,
physical examination and review of medical charts. Risk factors for seizures, clinical manifestations, associated comorbidities, and
antiphospholipid antibodies were evaluated. Results. Nine (10.2%) patients with seizures were identiﬁed, 77.8% had convulsions
onset after PAPS diagnosis. Mean age, gender, and race were comparable in groups with or without seizures. Interestingly, a higher
frequency of current smoking (44.4 versus 10.1%, P = 0.019) was observed in the ﬁrst group. Stroke, Sneddon’s syndrome,
and livedo reticularis were more frequent in PAPS patients with seizures than those without seizures, although not statistically
signiﬁcant (P>0.05). Comparison between patients with seizures onset after PAPS diagnosis (n = 7) and those without
convulsions (n = 79) demonstrated a higher frequency of current smoking (42.9 versus 10%, P = 0.042) and stroke in the
ﬁrst group (71.4 versus 30.4%, P = 0.041). Regression analysis conﬁrmed that smoking (P = 0.030) and stroke (P = 0.042)
were independently associated to seizures. Conclusion. About 10.2% of PAPS patients had convulsions, predominantly after PAPS
diagnosis, and seizures were associated to current smoking and stroke.
1.Introduction
Antiphospholipid syndrome (APS) is a systemic autoim-
mune disorder characterized by the presence of arterial or
venous thrombosis and/or recurrent fetal loss, in addition
to serum antiphospholipid (aPL) antibodies, mainly lupus
anticoagulant (LA) and anticardiolipin antibody (aCL) [1].
APScanoccurinpersonswithoutanunderlyingsystemic
autoimmune disease (primary APS or PAPS) or in the
presenceofothersystemicautoimmunediseases,particularly
systemic lupus erythematosus (SLE) [1–3].
ThefrequencyofaPLrangesfrom1to10%inthegeneral
population; however, the exact prevalence of PAPS is not
known.Basedonalimitednumberofuncontrolledandnon-
risk-stratiﬁed studies, asymptomatic aPL-positive patients
have 0 to 4% risk of annual thrombosis [4].
Inthearterialterritory,thecentralnervoussystem(CNS)
is the most aﬀected organ, up to 22% of PAPS patients,
usually in the form of stroke or transient ischemic attacks
(TIA). Additional CNS manifestations described in these
patients are, chorea, migraine, transverse myelitis, cognitive
impairment and epileptic seizures [5–7].
The association between the presence of aPL and epilep-
tic seizures has been studied in both animal models [8]
and in large cohort studies, especially in association with
SLE patients [9]. Previous studies suggested that aPL may
have a direct eﬀect on seizure genesis by increasing neu-
ronal excitability through inhibition of γ-aminobutyric acid
receptor-ion channel complex [10] or as consequence of
antibody binding to neurons [8]. Other studies concluded
thatepilepticseizuresinpatientswithaPLmaybetheexpres-
sion of ischemic events secondary to hypercoagulability [11,
12].
However, there are no studies evaluating seizure fre-
quency speciﬁcally in PAPS patients. Therefore we sought to
determinethefrequencyandriskfactorsforepilepticseizures2 Clinical and Developmental Immunology
in a cohort of PAPS. We also analyzed clinical and laboratory
featuresassociatedwiththeoccurrenceofsingleepisodesand
recurrence of epileptic seizures.
2. Methods
2.1. Patients. The records of 320 APS patients followed
regularly at the Antiphospholipid Syndrome Outpatient
Clinic of the Rheumatology Division, Hospital das Cl´ ınicas
da Faculdade de Medicina da Universidade de S˜ ao Paulo,
were reviewed. Patients who had secondary causes of APS,
suchasSLE,rheumatoidarthritis,orvasculitiswereexcluded
fromthisstudy.Furthermore,noselectedpatienthadspeciﬁc
antibodies for SLE, anti-double-stranded DNA, or anti-
Sm antibodies. Patients with seizures secondary to acute
metaboliccausessuchasuremia,hypertension,diabetesmel-
litus,andelectrolyticabnormalitieswereexcluded.Therefore
88 patients (mean age 40.6 ± 11.1 years; 91% women) with
PAPS, according to Sydney’s criteria [13] were included.
All subjects provided informed consent, and the study was
approved by the local Ethical Committee.
2.2. Demographic and Clinical Data, Comorbidities, and
Medications. Demographic, clinical, and therapeutic data
were obtained through a standard interview, physical exam-
ination, and exhaustive review of medical charts. The
date of PAPS diagnosis, as well as the onset of epileptic
seizures, was registered. Variables collected included age,
gender, race, weight, height, and body mass index (BMI)
(weight/height2). Clinical and therapeutic data, including
disease duration, thrombotic and obstetric manifestations,
stroke, acute myocardial infarction, chronic comorbidities
such as hypertension, diabetes, dyslipidemia, metabolic
syndrome, current or previous history of smoking, alco-
holism, and medication history of warfarin, heparin, aspirin,
anticonvulsants, and antimalarial drugs were obtained from
the medical records and interviews. Diabetes mellitus was
deﬁned as fasting blood glucose >126mg/dL or current use
ofinsulinand/ororalhypoglycemicdrugs.Hypertensionwas
deﬁned as systolic blood pressure >140mmHg or diastolic
bloodpressure>90mmHgorcurrentuseofantihypertensive
drugs [14]. Metabolic syndrome and dyslipidemia were
deﬁned according to the International Diabetes Federation
(IDF) consensus [15].
2.3.NeurologicEvaluation. Seizureswereclassiﬁedaccording
to the International League Against Epilepsy criteria [16, 17].
Electroencephalograms (EEGs) were recorded in the interic-
tal period in a 16-channel analog or 32-channel digital EEG
recorder with the International 10–20 System of electrode
placement for 20 to 30 minutes. We tabulated the presence
and localization of interictal epileptiform abnormality and
slow wave abnormality. Magnetic resonance imaging (MRI)
was performed in all patients who had seizures or other CNS
manifestations [18].
2.4. Autoantibodies. Serum IgG and IgM anticardiolipin
(aCL) antibodies were measured at least twice with an
interval of 6 weeks by ELISA as previously described
[19], using a commercially available kit (Quanta Lite ACA,
INOVA Diagnostics, USA). According to the manufacturer’s
recommendationsandSydneycriteria[13],onlytitersofaCL
≥40GPL or MPL were considered positive. Lupus antico-
agulant was measured according to international guidelines
using activated partial thromboplastin time (APTT, Diag-
nostica Stago, France) and diluted Russell’s viper venom
time (dRVVT, Trinity Biotech, Wicklow, Ireland) [20]. IgG
and IgM anti-beta2-glycoprotein were measured once using
a commercial ELISA kit according to the manufacturer’s
instructions (Quanta Lite, INOVA Diagnostics Inc, CA,
USA). As described in the kit, the positive standard used to
constructthecalibrationcurvecamefromtheRheumatology
Lab, Seton Hall University, St. Joseph’s Hospital and Medical
Center. Only titers of ACL and anti-beta2-glycoprotein
>40U/mL were considered positive.
In order to exclude systemic lupus erythematosus and
other connective diseases such as Sjogren’s syndrome,
we assessed the following antibodies: anti-double-stranded
DNA (anti-dsDNA) antibodies were detected by indirect
immunoﬂuorescence using as substrates Crithidia luciliae
[21]. Hemagglutination assay with rabbit thymus extract was
used to determine the presence of antibodies to RNP and Sm
proteins [22].
2.5. Statistical Analysis. Evaluation was performed using the
computer program GraphPad. Results are shown as mean ±
standard deviation or percentage. Chi-square, Fisher’s exact,
Student’s t- and Mann-Whitney tests were used for com-
parisons between both groups of patients, with or without
seizures, when applicable. Logistic regression was used
to analyze associations between seizures and the several
evaluated features (dependent variable). P values < 0.05 were
considered to be statistically signiﬁcant.
3. Results
Seizures were identiﬁed in 9 (10.2%) of 88 PAPS patients.
Two of them (22.2%) had seizures onset before and 7
(77.8%) patients after the diagnosis of PAPS. Five of nine
(55.6%) patients had partial complex seizures, 3 (33.3%)
had generalized tonic-clonic seizures, and 1 (11.1%) had
focal seizure. Interictal EEG was done in 7/9 patients and
showed epileptiform activity in 6 patients. MRI was done
in all patients, and the majority (6/9) of the patients had
evidence of ischemic lesions (Table 1).
3.1. Comparative Analysis between PAPS Patients with or
without Seizures. Current smoking was more observed in
PAPS patients with seizures than those without this neu-
rological abnormality (44.4 versus 10.1%; P = 0.019).
In addition, previous history of smoking was also more
frequently observed in PAPS with seizures when compared
to the other patients (66.7 versus 35.4%, P = 0.083),
although it did not reach statistical signiﬁcance. Similarly,
stroke (66.7 versus 30.4%, P = 0.057), Sneddon’s syndrome
(44.4 versus 15.2%, P = 0.053), and livedo reticularisClinical and Developmental Immunology 3
Table 1: Characteristics of the 9 PAPS patients with epileptic seizures.
Thrombotic
event Comorbidity
Age
(years)
sex, race
Seizure
onset after
PAPS
LR Seizure type >1s e i z u r e MRI EEG Drugs
1 DVT Hypothyroidism 49, F, C − + Generalized
tonic-clonic
+ NL
EA in
frontal
region
CBZ, PHT,
PB, WAR
2 Stroke Hypertension 52, F, C + + Partial
complex
−
Right fronto-
parietooccipital
stroke
NL PB, ASA
3S t r o k e
Chorea
gravidarum,
preeclampsia
29, F, C + −
Partial
complex with
secondary
generalization
+
Left frontal and
basal ganglia
hyperintense
lesions
EA in left
parietooc-
cipital
region
PB, PHT,
CLB, GBP,
ASA
4 DVT, PTE, stroke,
miscarriages Rheumatic fever 32, F, C + + Partial +
Right temporo-
parietooccipital
stroke
EA in right
parietal
region
CLB, PHT,
TPM,
WAR
5 DVT, miscarriages Depression 51, F,
Mul
− − Partial
complex
+
Left
periventricular
and parietal
stroke
EA in left
parietal
region
CBZ,
OXC,
WAR
6 Renal TMA, stroke,
TIA, miscarriages
Renal
transplantation
depression
53, F, C + −
Partial
complex with
secondary
generalization
−
Left
frontotemporal
srtroke
EA in left
temporal
region
PHT,
WAR, ASA
7 Thrombocytopenia,
stroke
Hypothyroidism
splenectomy
45, M,
C + −
Partial
complex with
secondary
generalization
−
Stroke of
territory of the
middle cerebral
artery
EA in left
temporal
region
CBZ, ASA
8 DVT,
thrombocytopenia — 35, M,
C + − Generalized
tonic-clonic
− NL ND PB, PHT,
WAR
9 DVT,
thrombocytopenia
Compulsive
gambler
53, M,
C + + Generalized
tonic-clonic
− NL ND PHT, WAR
ASA: aspirin; CBZ: carbamazepine; C: Caucasian; CLB: clobazam; DVT: deep venous thrombosis; EA: epileptiform activity; EEG: electroencephalogram; F:
female;GBP:gabapentin;M:male;Mul:mulatto;NL:normal;ND:notdone;PAPS:primaryantiphospholipidsyndrome;PTE:pulmonarythromboembolism;
TMA: microangiopathic; OXC: oxcarbazepine; PB: phenobarbital; PHT: phenytoin; TPM: topiramate; WAR: warfarin.
(66.7 versus 30.4%, P = 0.057) had a trend to be more
frequently observed in PAPS patients with epileptic seizures.
No diﬀerence regarding other clinical APS manifestations,
disease duration, risk factors for cerebrovascular diseases,
medications, and antiphospholipid antibodies was observed
between the groups (P>0.05) (Table 2).
3.2. Comparative Analysis between Patients with Onset of
Seizures after PAPS Diagnosis and Those without Seizures.
The comparison of the 7 patients with onset of seizures
after PAPS diagnosis and those without seizures (n = 79)
demonstrated a higher frequency of current smoking (42.9
versus 10.1%, P = 0.042) and stroke (71.4 versus 30.4%,
P = 0.041) in the ﬁrst group (Table 3). Regression analysis
revealed that smoking (OR: 7.37, 95% CI: 1.21–44.83, P =
0.030) and stroke (OR: 6.5, 95% CI: 1.07–39.44, P = 0.042)
were independent variables associated to seizures.
3.3. Comparative Analysis between Patients with Single and
Recurrent Epileptic Seizures. Four of 9 (44.4%) patients
had recurrent seizures and 5 (55.6%) had a single seizure.
Patients with recurrent seizures had higher levels of IgG
anticardiolipin (95 (32–120) versus 20 (0–74) GPL, P =
0.035) and less frequently livedo reticularis (25 versus 100%,
P = 0.048) than patients with a single seizure. The other
parameters were alike between the groups (P>0.05).
4. Discussion
In this group of 88 PAPS patients, 9 (10.2%) had seizures.
The frequency of seizures in previous studies was about 7%
[5–7]. Generalized tonic-clonic and complex focal seizures
were the most common seizures observed in this study.
Current smoking was the only feature associated with
seizures in our PAPS patients with this neurological man-
ifestation. Similar results were observed in a large cohort
of healthy women studied prospectively over 15 years after
adjustment for stroke and other potential confounding
factors [23]. One possible biologic explanation is a direct
eﬀect of nicotine, which is an excitatory neurotransmitter
that enhances glutamate release. In predisposed mice, nico-
tine has dose-dependent convulsive eﬀects: at low doses,4 Clinical and Developmental Immunology
Table 2: Comparisons of demographic, clinical, and laboratory features, vascular risk factors, and medications between the 9 PAPS patients
with seizures and PAPS patients without seizures (n = 79).
PAPS with seizures PAPS without seizures P values
n = 9 n = 79
Age, years 44.6 ±10.74 0 .1 ±11.2 0.261
White race, n (%) 7 (77.8) 65 (82.3) 0.665
Female gender, n (%) 7 (77.8) 65 (82.3) 0.665
Body mass index, kg/m2 27.8 ± 3.12 8 .0 ±7.5 0.933
Arterial events, n (%) 6 (66.7) 38 (48.1) 0.484
Venous events, n (%) 4 (44.4) 49 (62.0) 0.474
Obstetric events, n (%) 3 (33.3) 31 (39.2) 1.000
Thrombocytopenia, n (%) 2 (22.2) 19 (24.1) 1.000
Livedo reticularis, n (%) 6 (66.7) 24 (30.4) 0.057
Stroke, n (%) 6 (66.7) 24 (30.4) 0.057
Sneddon’s syndrome, n (%) 4 (44.4) 12 (15.2) 0.053
Pulmonary thromboembolism, n (%) 1 (11.1) 19 (24.1) 0.678
Deep venous thrombosis, n (%) 4 (44.4) 40 (50.6) 0.680
Angina, n (%) 1 (11.1) 7 (8.9) 1.000
Acute myocardial infarction, n (%) 0 1 (1.2) 1.000
Sedentarism, n (%) 6 (66.7) 50 (63.3) 1.000
Disease duration, months 88.4 ±94 94.6 ±64.3 0.398
Metabolic syndrome, n (%) 0 17 (21.5) 0.270
Diabetes, n (%) 0 6 (7.6) 0.874
Systemic hypertension, n (%) 4 (44.4) 37 (46.8) 0.892
Previous history of smoking, n (%) 5 (55.5) 28 (35.4) <0.001
Current smoking, n (%) 4 (44.4) 8 (10.1) 0.019
Alcoholism, n (%) 1 (11.1) 0 0.102
Heparin use, n (%) 6 (66.7) 40 (50.6) 0.575
Current chloroquine use, n (%) 2 (22.2) 37 (46.8) 0.153
Statin use, n (%) 4 (44.4) 20 (25.3) 0.680
IgG anticardiolipin levels, GPL 55.1 ±45.94 0 .0 ±46.2 0.357
IgG anticardiolipin, n (%) 7 (77.8) 44 (55.7) 0.293
IgM anticardiolipin levels, MPL 17.7 ±19.92 9 .9 ±40.2 0.373
IgM anticardiolipin, n (%) 5 (55.6) 40 (50.6) 1.000
Lupus anticoagulant, n (%) 6 (66.7) 60 (75.9) 0.839
IgG anti-beta2-glycoprotein I, U/mL 26.6 ±31.32 22.6 ±35.02 0.809
IgG anti-beta2-glycoprotein I, n (%) 2 (22.2) 13 (20.9) 0.669
IgM anti-beta2-glycoprotein I, U/mL 12.0 ±12.41 4 .5 ±32.4 0.862
IgM anti-beta2-glycoprotein I, n (%) 1 (11.1) 7 (8.9) 1.000
Data expressed as mean ± standard deviation or percentage; PAPS: primary antiphospholipid syndrome; n = number of patients; SD = standard deviation.
the onset of seizures was delayed [24], whereas at high
doses, nicotine caused convulsions [25]. Nicotine is also a
stimulant and increases blood pressure and impairs sleep.
In addition, smoking causes tissue hypoxia due to chronic
carbon monoxide exposure [26]. All these factors may
indirectly lead to seizures. Unfortunately, we did not have
data regarding nicotine dosage in our patients. However,
since the presence of aPL increases neuronal excitability, the
association with nicotine may represent a risk factor for
seizure genesis in these patients [25]. PAPS patients should
therefore strongly be discouraged from nicotine abuse.
Seizures before PAPS diagnosis were identiﬁed in 2 out
of 9 patients. Although we do not know if these patients had
positive aPL before the thrombotic event, we did not exclude
these patients because autoantibodies have been shown to
appear in the systemic circulation years before the onset of
autoimmune diseases [27].
Seizures occurred after PAPS diagnosis in 7/9 (77.8%)
patients. Both current smoking and stroke were indepen-
dently associated with seizures in these patients. Previous
studies have identiﬁed stroke as a risk factor for seizures
in APS and SLE [9, 18]. Furthermore, most patients had
evidence of ischemic lesions on MRI. These ﬁndings suggest
that PAPS patients with new onset of seizures should be
screened for ischemic cerebral lesions, independently of their
previous treatment for APS. In addition, it is well knownClinical and Developmental Immunology 5
Table 3: Comparisons of demographic, clinical, and laboratory features, vascular risk factors, and medications between the 7 PAPS patients
with seizures after APS diagnosis and those without seizures (n = 79).
PAPS with epileptic
seizures after APS onset
n = 7
PAPS without
epileptic seizures
n = 79
P value
Age, years 42 ±10.34 0 .1 ±11.2 0.670
White race, n (%) 5 (71.4) 65 (82.3) 0.610
Female gender, n (%) 5 (71.4) 65 0.610
Body mass index, kg/m2 27.5 ±2.92 8 .0 ±7.5 0.866
Arterial events, n (%) 5 (71.4) 38 (48.1) 0.433
Venous events, n (%) 2 (28.6) 49 (62.0) 0.115
Obstetric events, n (%) 2 (28.6) 31 (39.2) 0.703
Thrombocytopenia, n (%) 2 (28.6) 19 (24.1) 1.000
Livedo reticularis, n (%) 4 (57.1) 24 (30.4) 0.208
Stroke, n (%) 5 (71.4) 24 (30.4) 0.041
Sneddon’s syndrome, n (%) 3 (42.9) 12 (15.2) 0.098
Pulmonary thromboembolism, n (%) 1 (14.3) 19 (24.1) 0.678
Deep venous thrombosis, n (%) 2 (28.6) 40 (50.6) 0.434
Angina, n (%) 07 ( 8 . 9 ) 1.000
Acute myocardial infarction, n (%) 01 ( 1 . 3 ) 1.000
Sedentarism, n (%) 5 (71.4) 50 (63.3) 1.000
Disease duration, months 92.6 ±101.99 4 .6 ±64.3 0.470
Metabolic syndrome, n (%) 0 17 (21.5) 0.336
Diabetes, n (%) 06 ( 7 . 6 ) 1.000
Systemic hypertension, n (%) 3 (42.9) 37 (46.8) 1.000
Previous history of smoking, n (%) 5 (71.4) 28 (35.4) 0.101
Current smoking, n (%) 3 (42.9) 8 (10.1) 0.042
Alcoholism, n (%) 1 (14.3) 0 1.000
Heparin use, n (%) 4 (57.1) 37 (46.8) 1.000
Current chloroquine use, n (%) 2 (28.6) 37 (46.8) 0.448
Statin use, n (%) 0 20 (25.3) 0.193
IgG anticardiolipin levels, GPL 57.4 ±50.44 0 .0 ±46.3 0.347
IgG anticardiolipin, n (%) 5 (71.4) 44 (55.7) 1.000
IgM anticardiolipin levels, MPL 19.9 ±21.62 9 .9 ±40.2 0.518
IgM anticardiolipin, n (%) 4 (57.1) 40 (50.6) 1.000
Lupus anticoagulant, n (%) 5 (71.4) 60 (75.9) 1.000
Data expressed as mean ± standard deviation or percentage; PAPS: primary antiphospholipid syndrome; n = number of patients; SD = standard deviation.
that APS patients are prone to atherosclerosis due to several
cardiovascular factors [28, 29].
Single seizures were observed in 5 of 9 patients. Inter-
estingly, livedo reticularis was more frequently observed in
these patients when compared to patients with recurrent
epileptic seizures. This ﬁnding is diﬃcult to explain, since
livedo reticularis is commonly linked to stroke, and this
neurological event was positively associated with seizures
after APS onset in our patients.
In PAPS patients with recurrent epileptic seizures, we
observed signiﬁcant higher IgG anticardiolipin levels when
compared to patients with single seizures episodes, reinforc-
ingtheroleofaPLinseizuregenesis.Theassociationbetween
higher titers of antiphospholipid antibodies and seizures has
been previously demonstrated [8, 10].
Diﬀerent from previous studies, this paper evaluated the
frequency of seizures and their risk factors speciﬁcally in pri-
mary APS according to the currently accepted criteria [13].
Indeed, it is known that in SLE, the main disease associated
to secondary APS, there are multiple causes for seizures,
such as nervous central system activity, vasculitis, stroke, and
meningoencephalitis [9, 30]. Moreover, all selected patients
were negative for lupus-speciﬁc autoantibodies. Other addi-
tional beneﬁt is the overview analysis of several risk factors
for convulsions, allowing a more accurate evaluation of the
relevance of each risk factor for convulsions.
In conclusion, we observed the occurrence of seizures in
10.2% of patients with PAPS, which occurred predominantly
after the diagnosis of this disorder, and were independent
factor associated with current smoking and stroke. These6 Clinical and Developmental Immunology
ﬁndings suggest that the pathogenic mechanism of seizures
inPAPSisconsequenttoischemiccerebraleventsinaddition
to excitatory mechanism of both nicotine and aPL. All PAPS
patients with new onset of seizures should be screened for
ischemiccerebralevents.Furthermore,ourdatareinforcethe
need for smoking cessation, as well as rigorous control of
cardiovascular risk factors in these patients.
5. Key Messages
(1) About 10.2% of patients with primary antiphospho-
lipid syndrome have seizures.
(2) Seizures in primary antiphospholipid syndrome
occur mainly after the APS diagnosis and are linked
to current smoking and stroke.
(3) Treatment of seizures in APS includes the need for
smoking cessation, as well as rigorous control of
cardiovascular risk factors in these patients.
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